
|Videos|May 3, 2021
Considerations for Selecting Therapy in RRMM
Author(s)Sagar Lonial, MD, FACP, FASCO
Sagar Lonial, MD, FACP, reviews targeted therapy options, and how they differ from other therapeutic approaches for relapsed/refractory myeloma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Capivasertib Combo Earns FDA Approval in PTEN-Deficient Metastatic HSPC
2
FDA Approves Adjuvant Belzutifan/Pembrolizumab in Clear Cell RCC Post Nephrectomy
3
Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer
4
Tisa-Cel Yields Enduring Remissions in Younger High-Risk B-ALL Population
5








































































